FK962|cas:283167-06-6|西域试剂

FK962,99.89%

产品编号：Bellancom-133025| CAS NO：283167-06-6| 分子式：C₁₄H₁₇FN₂O₂| 分子量：264.30

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-133025	￥1500.00	杭州北京（现货）
Bellancom-133025	￥2300.00	杭州北京（现货）
Bellancom-133025	￥4500.00	杭州北京（现货）
Bellancom-133025	￥6500.00	杭州北京（现货）
Bellancom-133025	￥9000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FK962

产品介绍

FK962 是生长抑素 (somatostatin) 释放的增强剂，具有认知增强作用。

生物活性

FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties.

体外研究

FK962 (1 nM-1 μM) significantly enhances high K⁺-evoked somatostatin release from rat hippocampal slices. FK962 also significantly reduces somatostatin-induced inhibition of Ca²⁺ channels at 1-100 nM in single rat hippocampal neurons using whole-cell patch-clamp.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

FK962 (0.1, 0.3 or 1.0 mg/kg; i.p.) and Donepezil (a single dose of 1 mg/kg) act synergistically to improve cognition in rats: as an add-on therapy for Alzheimer's disease.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lister Hooded rats, weighing approximately 270-300
Dosage:	0.1, 0.3 or 1.0 mg/kg; Donepezil was given as a single dose of 1 mg/kg
Administration:	Administered i.p.
Result:	Resulted in minimal cognition enhancement when given separately. Combination showed a significantly greater effect on cognition.

体内研究

FK962 (0.1, 0.3 or 1.0 mg/kg; i.p.) and Donepezil (a single dose of 1 mg/kg) act synergistically to improve cognition in rats: as an add-on therapy for Alzheimer's disease.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lister Hooded rats, weighing approximately 270-300
Dosage:	0.1, 0.3 or 1.0 mg/kg; Donepezil was given as a single dose of 1 mg/kg
Administration:	Administered i.p.
Result:	Resulted in minimal cognition enhancement when given separately. Combination showed a significantly greater effect on cognition.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (945.89 mM; Need ultrasonic)

H₂O : 2 mg/mL (7.57 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7836 mL	18.9179 mL	37.8358 mL
5 mM	0.7567 mL	3.7836 mL	7.5672 mL
10 mM	0.3784 mL	1.8918 mL	3.7836 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.87 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (7.87 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (7.87 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (7.87 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (7.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。